natgillin/translations-raw huggingface dataset:
It blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to reproduce itself in the cells it has infected. 
Zavira delovanje reverzne transkriptaze, tj. encima, ki ga tvori virus HIV in ki virusu omogoča, da se razmnožuje v celicah, ki jih je okužil.
It also noted that there is little information on the benefits of treatment that include a protease inhibitor in patients who have been treated with Sustiva in the past but which stopped working, although there is no evidence to suggest that protease inhibitors may not work in these patients. 
Poudarila je tudi, da je malo informacij o koristih zdravljenja z zaviralcem proteaze pri bolnikih, ki so bili v preteklosti zdravljeni z zdravilom Sustiva, ki je prenehalo učinkovati, čeprav ni dokazov, da zaviralci proteaze pri teh bolnikih ne bi bili učinkoviti.
Sustiva has shown benefit in controlling HIV infection in three main studies involving over 1,100 adults. 
Zdravilo Sustiva je pri obvladovanju okužbe z virusom HIV izkazalo koristi v treh glavnih študijah, v katere je bilo vključenih več kot 1 100 odraslih.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sustiva have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Sustiva upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Sustiva must not be used in patients with severe liver disease. 
Zdravila Sustiva ne smejo uporabljati bolniki z resnimi obolenji jeter.
Sustiva does not cure HIV infection or AIDS, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS. 
Zdravilo Sustiva ne ozdravi okužbe z virusom HIV ali aidsa, vendar pa lahko upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
The active substance in Sustiva, efavirenz, is a non-nucleoside reverse transcriptase inhibitor (NNRTI). 
Zdravilna učinkovina v zdravilu Sustiva, efavirenz, je nenukleozidni zaviralec reverzne transkriptaze (NNRTI).
The Sustiva combination was more effective than the combination without Sustiva: 70% and 30% of the patients, respectively, had viral loads below 500 copies/ml after 48 weeks; 
Kombinacija z zdravilom Sustiva je bila učinkovitejša od kombinacije brez njega: 70 % oziroma 30 % bolnikov je imelo po 48 tednih virusno breme nižje od 500 kopij/ml;
By blocking this enzyme, Sustiva, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level. 
Zdravilo Sustiva, ki se jemlje v kombinaciji z drugimi protivirusnimi zdravili, z zaviranjem tega encima zmanjša količino virusa HIV v krvi in jo ohranja na nizki ravni.
The most common side effect with Sustiva (seen in more than 1 patient in 10) is rash. 
Najpogostejši neželeni učinek zdravila Sustiva (ki se je pojavil pri več kot 1 bolniku od 10) je izpuščaj.
Taking Sustiva with food may lead to an increase in the frequency of side effects. 
Jemanje zdravila Sustiva skupaj s hrano lahko poveča pogostnost neželenih učinkov.
Sustiva is an antiviral medicine that is used together with other antiviral medicines to treat patients aged 3 months or older and weighing at least 3.5 kg, who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). 
Zdravilo Sustiva je protivirusno zdravilo, ki se skupaj z drugimi protivirusnimi zdravili uporablja pri bolnikih, starejših od treh mesecev, in s telesno maso vsaj 3,5 kg, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
In all of the studies, the main measure of effectiveness was the number of patients with undetectable levels of HIV 1 in their blood (viral loads) after 24 or 48 weeks of treatment: 
V vseh študijah je bilo glavno merilo učinkovitosti število bolnikov, ki so imeli po 24 ali 48 tednih zdravljenja v krvi nezaznavno koncentracijo virusa HIV 1 (virusno breme):
For more information about treatment with Sustiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Sustiva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The Agency noted that Sustiva has not been studied adequately in patients with advanced disease (CD4 cell counts below 50 cells/mm3) or after treatment with protease inhibitors (another type of antiviral medicine) that was not working. 
Ugotovila je, da zdravilo Sustiva ni bilo ustrezno raziskano pri bolnikih z napredovalo boleznijo (številom celic CD4, nižjim od 50 celic/mm3) ali po zdravljenju z zaviralci proteaze (drugo vrsto protivirusnega zdravila), ki ni bilo uspešno.
67% of the adults treated with Sustiva in combination with zidovudine and lamivudine had viral loads below 400 copies/ml after 48 weeks, compared with 54% of the patients treated with Sustiva and indinavir, and 45% of the patients treated with indinavir, lamivudine and zidovudine; 
Po 48 tednih je bilo virusno breme nižje od 400 kopij/ml pri 67 % odraslih, zdravljenih z zdravilom Sustiva v kombinaciji z zidovudinom in lamivudinom, v primerjavi s 54 % bolnikov, zdravljenih z zdravilom Sustiva in indinavirjem, in 45 % bolnikov, zdravljenih z indinavirjem, lamivudinom in zidovudinom;
For practical information about using Sustiva, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Sustiva naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
• in the first study, Sustiva in combination with lamivudine and zidovudine or with indinavir (other antiviral medicines) was compared with the combination of indinavir, lamivudine and zidovudine. 
• v prvi študiji so zdravilo Sustiva v kombinaciji z lamivudinom in zidovudinom ali z indinavirjem (drugimi protivirusnimi zdravili) primerjali s kombinacijo indinavirja, lamivudina in zidovudina.
How is Sustiva used? 
Kako se zdravilo Sustiva uporablja?
Sustiva is also commonly associated with dizziness, headache, nausea (feeling sick) and tiredness. 
Zdravilo Sustiva pogosto povezujejo tudi z omotico, glavobolom, navzejo (siljenjem na bruhanje) in utrujenostjo.
Sustiva can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection. 
Predpisovanje in izdaja zdravila Sustiva je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
See the package leaflet for further details. 
Za več informacij glejte navodilo za uporabo.
• the third study compared adding Sustiva or placebo (a dummy treatment) to a combination of antiviral medicines that included indinavir and two other antiviral medicines, in patients who had already been receiving treatment for HIV infection. 
• v tretji študiji so primerjali dodajanje zdravila Sustiva ali placeba (zdravila brez zdravilne učinkovine) kombinaciji protivirusnih zdravil, ki je vključevala indinavir in dve drugi protivirusni zdravili, pri bolnikih, ki so se že zdravili zaradi okužbe z virusom HIV.
• the second study compared Sustiva in combination with nelfinavir and two other antiviral medicines with the same combination without Sustiva. 
• v drugi študiji so zdravilo Sustiva v kombinaciji z nelfinavirjem in dvema drugima protivirusnima zdraviloma primerjali z enako kombinacijo, vendar brez zdravila Sustiva.
For the full list of all side effects reported with Sustiva, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Sustiva, glejte navodilo za uporabo.
The dose of Sustiva may need to be adjusted in patients taking certain other medicines at the same time. 
Poleg tega je pri sočasnem jemanju določenih drugih zdravil včasih treba prilagoditi odmerek zdravila Sustiva.
How does Sustiva work? 
Kako zdravilo Sustiva deluje?
More patients receiving Sustiva had viral loads below 400 copies/ml than those taking placebo after 24 weeks 
Po 24 tednih je bilo virusno breme nižje od 400 kopij/ml pri več bolnikih, ki so prejemali zdravilo Sustiva, kot tistih, ki so prejemali placebo.
These and other effects are described in more detail in section 4.10 on overdose. 
Ti in drugi učinki so podrobneje opisani v poglavju 4.10 o prevelikem odmerjanju.
Since effects are dose dependent they are more pronounced in small children than adults. 
Ker so učinki odvisni od odmerka, so ti pri majhnih otrocih izrazitejši kot pri odraslih.
See the detailed instructions and pictures in the end of this leaflet. 
Oglejte si podrobna navodila in slike na koncu tega navodila za uporabo.
Once opened use by... 
Po odprtju porabite do ...
The product can be dosed up to 5 times during each event. 
Zdravilo se lahko odmeri do 5-krat med vsakim dogodkom.
Dosing should be performed by an adult. 
Odmerjanje mora opraviti odrasla oseba.
The level and duration of sedation is dose dependent. 
Stopnja in trajanje sedacije sta odvisna od odmerka.
Make sure that the carton is closed properly. 
Prepričajte se, da je kartonska škatla pravilno zaprta.
Do not drive as sedation and changes in blood pressure may occur. 
Ne vozite, saj lahko nastopijo sedacija in spremembe v krvnem tlaku.
If this occurs the animal should be kept warm. 
Če se to zgodi, je treba poskrbeti, da je živali toplo.
Metabolism accounts for more than 98% of the elimination. 
Presnova poskrbi za več kot 98 % izločanja.
This multipack is not intended to be supplied directly to the animal owner. 
To skupno pakiranje ni namenjeno oskrbi neposredno imetniku živali.
Instructions for opening the package: 
Navodila za odprtje pakiranja:
Pregnant women should avoid contact with the product. 
Nosečnice naj se izogibajo stiku z zdravilom.
Hold the plunger with your left hand. 
Držite bat z levo roko.
Typical signs of anxiety and fear are panting, trembling, pacing (frequent change of place, running around, restlessness), seeking people (clinging, hiding behind, pawing, following), hiding (under furniture, in dark rooms), trying to escape, freezing (absence of movements), refusing to eat food or treats, inappropriate urination, inappropriate defecation, salivation, etc. 
Značilni znaki tesnobe in strahu so sopenje, tresenje, sprehajanje gor in dol (pogosto menjavanje mesta, tekanje okoli, nemirnost), zatekanje k ljudem (držanje pri ljudeh, skrivanje za njimi, dotikanje s tačko, sledenje), skrivanje (pod pohištvom, v temnih prostorih), poskusi pobega, otrpnjenost (odsotnost gibanja), zavračanje hrane ali priboljškov, neprimerno uriniranje, neprimerno iztrebljanje, slinjenje itd.
Blood pressure decreases slightly below normal levels. 
Krvni tlak se zniža nekoliko pod normalne vrednosti.
In extremely nervous, excited or agitated animals the response to the medicine may be reduced. 
Pri izjemno živčnih, razburjenih ali vznemirjenih živalih je lahko odziv na zdravilo manjši.
On the inner part of the carton: When closing, make sure that the pictures of the dogs are aligned and that the carton is closed properly. 
Na notranjem delu kartonske škatle: Pri zapiranju se prepričajte, da so slike psov poravnane in da je škatla pravilno zaprta.
In extremely nervous, excited or agitated animals, the levels of endogenous catecholamines are often high. 
Pri izjemno živčnih, razburjenih ali vznemirjenih živalih so ravni endogenih kateholaminov pogosto visoke.
Do not use in dogs obviously sedated from previous dosing. 
Ne uporabite pri psih, ki so očitno sedirani zaradi prejšnjega odmerka.
ATCvet code: QN05CM18. 
Oznaka ATC vet: QN05CM18.
Do not use in dogs with severe systemic disease (graded as ASA III-IV) e.g. end stage renal or liver failure. 
Ne uporabite pri psih s hudo sistemsko boleznijo (razvrščeno v razred ASA III-IV), npr. zadnjo fazo odpovedi ledvic ali jeter.
If the fear eliciting event continues and the dog shows signs of anxiety and fear again, re-dosing can be done when 2 hours has passed from the previous dose. 
Če se dogodek, ki je izzval strah, nadaljuje in pes znova kaže znake tesnobe in strahu, je ponovno odmerjanje mogoče, ko sta od prejšnjega odmerka minili 2 uri.
Its levels in the brain were from 3-fold to 6-fold higher than the levels in plasma. 
Ravni učinkovine so bile v možganih za 3- do 6-krat višje od tistih v plazmi.
QR code to be included + www.sileodog.com 
Dodana bo koda QR + www.sileodog.com
If sedation occurs, the dog should be kept warm. 
Če se pojavi sedacija, je treba poskrbeti, da je psu toplo.
Respiration rate can occasionally decrease. 
Občasno se lahko upočasni dihanje.
The first dose should be given as soon as the dog shows the first signs of anxiety, or when the owner detects a typical stimulus (e.g. sound of fireworks or thunder) for eliciting anxiety or fear in the respective dog. 
Prvi odmerek je treba dati takoj, ko pes pokaže prve znake tesnobe ali ko lastnik zazna značilne pojave (npr. zvok ognjemeta ali groma), ki pri posameznem psu izzovejo tesnobo ali strah.
IMPORTANT: The gel should not be swallowed. 
POMEMBNO: Gela pes ne sme pogoltniti.
Ventricular arrhythmias have also been reported. 
Poročali so tudi o ventrikularnih aritmijah.
Add a note on the carton after “Once opened use by...” to remind you when the 4 weeks has passed. 
Na škatlo dodajte opombo »Po odprtju porabi do ...«, da ne boste pozabili, kdaj bodo minili 4 tedni.
Unlike most other oral veterinary products, this product is not meant to be swallowed. 
Za razliko od večine drugih oralnih zdravil za uporabo v veterinarski medicini to zdravilo ni namenjeno temu, da bi ga žival pogoltnila.
Pharmacotherapeutic group: psycholeptics, hypnotics and sedatives. 
Farmakoterapevtska skupina: psiholeptiki, hipnotiki in sedativi.
If an overdose occurs, contact a veterinary surgeon as soon as possible. 
Če pride do prevelikega odmerjanja, se čim prej posvetujte z veterinarjem.
Oromucosal use. 
Oralna uporaba.
If symptoms occur, seek the advice of a physician. 
Če se pojavijo simptomi, se posvetujte z zdravnikom.
Do not use in dogs with severe cardiovascular disorders. 
Ne uporabite pri psih s hudimi boleznimi srca in ožilja.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the oromucosal gel contains: 
KAKOVOSTNA IN KOLIČINSKA SESTAVA En ml oralnega gela vsebuje:
When studied in rats, the distribution of dexmedetomidine into rat tissues was rapid and wide with concentrations higher than in plasma for many tissues. 
Ko so zdravilo preučevali pri podganah, je bila porazdelitev deksmedetomidina v tkiva podgan hitra in obsežna, pri čemer so bile v številnih tkivih koncentracije višje kot v plazmi.
Bodyweight of dog (kg) Number of dots 
Telesna masa psa (kg) Število pik
Overdose can cause excessive tiredness. 
Prevelik odmerek lahko povzroči čezmerno utrujenost.
The pharmacological response elicited by alpha-2 agonists (e.g. dexmedetomidine) in such animals may be reduced. 
Farmakološki odziv, ki ga izzovejo agonisti alfa-2 (npr. deksmedetomidin), je pri teh živalih lahko zmanjšan.
The maximum concentration of dexmedetomidine occurs at about 0.6 hours after intramuscular or oromucosal administration. 
Najvišja koncentracija deksmedetomidina nastopi približno 0,6 ure po intramuskularni ali oralni aplikaciji.
Respiratory and haemodynamic symptoms should be treated symptomatically. 
Simptome, povezane z dihali in hemodinamiko, je treba zdraviti simptomatsko.
The apparent volume of distribution of dexmedetomidine in dogs is 0.9 l/kg. 
Navidezni volumen porazdelitve deksmedetomidina pri psih je 0,9 l/kg.
4.8 Interaction with other medicinal products and other forms of interaction 
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij:
Remove and discard gloves. 
Odstranite in zavrzite rokavice.
Other ingredients: Brilliant blue (E133) and tartrazine (E102). 
Druge sestavine: briljantno modro FCF (E133) in tartrazin (E102).
The safety of administering Sileo to puppies younger than 16 weeks and dogs over 17 years of age has not been studied. 
Varnosti dajanja zdravila Sileo mladičem, mlajšim od 16 tednov, in psom, starejšim od 17 let, niso preučevali.
Move the ring-stop towards the other end of the plunger for choosing the correct dose based on your veterinarian's prescription. 
Premaknite zaporni obroček proti drugemu koncu bata, da izberete pravilni odmerek, ki ga je predpisal veterinar.
Known metabolites show no or negligible activity. 
Znani presnovki niso aktivni ali kažejo zanemarljivo aktivnost.
EU/2/15/181/002 (3 (1 x 3 ml) oral syringes) EU/2/15/181/003 (5 (1 x 3 ml) oral syringes) EU/2/15/181/004 (10 (1 x 3 ml) oral syringes) EU/2/15/181/005 (20 (1 x 3 ml) oral syringes) 
EU/2/15/181/002 (3 (1 x 3 ml) oralne brizge) EU/2/15/181/003 (5 (1 x 3 ml) oralnih brizg) EU/2/15/181/004 (10 (1 x 3 ml) oralnih brizg) EU/2/15/181/005 (20 (1 x 3 ml) oralnih brizg)
If the oromucosal gel is swallowed it will become ineffective. 
Če žival oralni gel pogoltne, bo postal neučinkovit..
Avoid skin, eye or mucosal contact. 
Preprečite stik s kožo, očmi ali sluznico.
In a pharmacokinetic study in dogs the oromucosal mean bioavailability of dexmedetomidine was 28%. 
V farmakokinetični študiji pri psih je bila povprečna biološka razpoložljivost deksmedetomidina po oralni uporabi 28 %.
Multipacks of 5, 10 and 20 oral syringes are also available but are intended to be supplied only to veterinarians. 
Na voljo so tudi skupna pakiranja po 5, 10 in 20 oralnih brizg, vendar so namenjena oskrbi samo veterinarjem.
Sileo may cause the following adverse reactions. 
Zdravilo Sileo lahko povzroči naslednje neželene učinke.
People with known hypersensitivity to dexmedetomidine or any of the excipients should avoid contact with the veterinary medicinal product. 
Osebe z znano preobčutljivostjo na deksmedetomidin ali katero koli pomožno snov naj se izogibajo stiku z zdravilom.
In the circulation, dexmedetomidine is largely bound to plasma proteins (93%). 
V sistemskem obtoku se deksmedetomidin obsežno veže na beljakovine v plazmi (93 %).
Each increment is shown as one dot on the plunger. 
Vsak prirastek označuje ena pika na batu.
The major metabolic routes in dogs are hydroxylation of a methyl substituent and further oxidation to a carboxylic acid or O-glucuronidation of the hydroxylated product. 
Glavne presnovne poti pri psih so hidroksilacija metilne skupine in nadaljnja oksidacija v karboksilno kislino ali O-glukuronidacija hidroksiliranega zdravila.
MANUFACTURER'S BATCH NUMBER Lot 
IZDELOVALČEVA ŠTEVILKA SERIJE Lot
The safety of administering dexmedetomidine to puppies younger than 16 weeks and dogs over 17 years of age has not been studied. 
Varnosti dajanja deksmedetomidina mladičem, mlajšim od 16 tednov, in psom, starejšim od 17 let, niso preučevali.
Multipacks of 5, 10 and 20 oral syringes are intended to be supplied only to veterinarians. 
Skupna pakiranja po 5, 10 in 20 oralnih brizg so namenjena oskrbi samo veterinarjem.
When administered via the oral mucosa, enhanced bioavailability is observed as a result of absorption in the oral cavity and the avoidance of first-pass metabolism in the liver. 
Kadar se zdravilo daje prek ustne sluznice, opazimo izboljšano biološko razpoložljivost zaradi absorpcije v ustni votlini in odsotnosti presnove prvega prehoda v jetrih.
MOVE RING 
PREMAKNITE OBROČEK
Each oral syringe is packed in an individual child-resistant carton. 
Vsaka oralna brizga je pakirana v posamezno kartonsko škatlo, varno za otroke.
Metabolites are excreted mainly in the urine with a minor fraction found in the faeces. 
Presnovki se izločajo predvsem z urinom, medtem ko so v blatu ugotovili manjšo frakcijo.
Keep the oral syringe in the carton in order to protect from light. 
Oralno brizgo shranjujte v škatli za zagotovitev zaščite pred svetlobo.
Dexmedetomidine is eliminated by biotransformation mainly in the liver, with a half-life in dogs ranging from 0.5 to 3 hours after oromucosal administration. 
Deksmedetomidin se izloča z biotransformacijo predvsem skozi jetra, razpolovni čas pa se pri psih po oralni aplikaciji giblje med 0,5 in 3 urami.
The product should be administered onto the oral mucosa between dog's cheek and gum at a dose of 125 micrograms/m2. 
Zdravilo se daje na ustno sluznico med lice in dlesen psa v odmerku 125 mikrogramov/m2.
Recap the oral syringe and return it to the outer package as the product is sensitive to light. 
Namestite pokrovček na oralno brizgo in jo vrnite v zunanjo ovojnino, saj je zdravilo občutljivo za svetlobo.
In case of skin contact wash the skin immediately with large amounts of water and remove contaminated clothes. 
V primeru stika s kožo nemudoma sperite z velikimi količinami vode in odstranite kontaminirana oblačila.
Pull the cap strongly while holding the barrel. 
POVLECITE POKROVČEK (MOČNO) Močno povlecite pokrovček, medtem ko držite cev.
Note the cap is very tight (pull, do not twist). 
Opomba: pokrovček je pritrjen zelo močno (povlecite, ne zasukajte).
Atipamezole (at the concentration of 5 mg/ml) dose in millilitres is one sixteenth (1/16th) of the dose volume of Sileo gel. 
Odmerek atipamezola (v koncentraciji 5 mg/ml) v mililitrih ustreza eni šestnajstini (1/16) volumskega odmerka gela Sileo.
Oral bioavailability of dexmedetomidine is poor due to extensive first-pass metabolism. 
Peroralna biološka razpoložljivost deksmedetomidina je slaba zaradi obsežne presnove prvega prehoda.
Information for the veterinary surgeon: 
Informacije za veterinarja:
The specific alpha-2 adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans but only experimentally to antagonize dexmedetomidine-induced effects. 
Specifični antagonist adrenergičnih receptorjev alfa-2, atipamezol, ki je odobren za uporabo pri živalih, je bil uporabljen pri ljudeh samo poskusno, za nevtralizacijo z deksmedetomidinom induciranih učinkov.
(for 5 x 1, 10 x 1 and 20 x 1 multipacks only) 
(samo za skupna pakiranja 5 x 1, 10 x 1 in 20 x 1)
PACKAGE SIZE 1 x 3 ml oral syringe 
VELIKOST PAKIRANJA 1 x 3 ml oralna brizga
Do not use this veterinary medicinal product after the expiry date which is stated on the oral syringe label and outer carton after “EXP”. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na nalepki oralne brizge in škatli poleg oznake »EXP«.
3 packs of (3 ml) oral syringes 5 packs of (3 ml) oral syringes 10 packs of (3 ml) oral syringes 20 packs of (3 ml) oral syringes 
3 pakiranja z (3 ml) oralnimi brizgami 5 pakiranj z (3 ml) oralnimi brizgami 10 pakiranj z (3 ml) oralnimi brizgami 20 pakiranj z (3 ml) oralnimi brizgami
Do not pull the plunger! 
Ne vlecite bata.
PHARMACEUTICAL FORM Oromucosal gel. 
FARMACEVTSKA OBLIKA Oralni gel.
In rodents alpha-2 adrenoceptor agonists reduce synthesis of NA, DA, 5-HT and the 5-HT precursor, 5-HTP (5-hydroxytryptophan), in the frontal cortex, hippocampus, striatum and hypothalamus and as a result decreases motor behaviour and signalling associated with distress. 
Pri glodavcih agonisti adrenergičnih receptorjev alfa-2 zmanjšajo sintezo NA, DA, 5-HT in predhodnika 5-HT, 5HTP (5-hidroksitriptofan), v frontalnem korteksu, hipokampusu, striatumu in hipotalamusu ter posledično zmanjšajo motorično vedenje in signalizacijo, povezano s čustveno stisko.
Water, purified 
Prečiščena voda
In addition to anxiolytic effect, dexmedetomidine has other well-known dose dependent pharmacological effects such as lowering of heart rate and rectal temperature, and peripheral vasoconstriction. 
Poleg anksiolitičnega učinka ima deksmedetomidin druge znane farmakološke učinke, odvisne od odmerka, kot so upočasnitev srčnega utripa, znižanje rektalne temperature in periferna vazokonstrikcija.
If the dose for the dog is more than 6 dots, half of the dose should be administered to the oral mucosa on one side of the dog's mouth and the other half of the dose onto the other side. 
Če je odmerek za psa večji kot 6 pik, je treba dati polovico odmerka na ustno sluznico na eno stran in drugo polovico odmerka na drugo stran.